Novel Antibody Therapeutics Congress

When

2019年10月10-11日
Registration from 8am

Where

英国,伦敦
London Heathrow Marriott Hotel

Novel Antibody Therapeutics Congress
-新抗体医药学会-
日期:2019年10月10-11日
地点:英国,伦敦,London Heathrow Marriott Hotel
Choose your language
Chinese
Japanese
Korean
English

Novel Antibody Therapeutics Congress

推动抗体与蛋白质医生药物进化的研究方面、技术方面、事业方面之最新趋势

这次学会将安排有以配合癌症治疗的抗体医药最新发展为焦点的单元,探讨双特异性抗体技术的最新发展,以及探索新抗体和抗体模拟形式的潜力。此外也有以查核点抑制剂为焦点的单元,介绍针对治疗用的PD1,PD-L1和CTLA4的进展,以及新生物标记物的发现和标靶化的研究。

“I liked the fact that the conference was really focused ... allowing to learn and discuss specific subjects with experts in the field”

“Excellent opportunity to discuss topics in detail and to network”.

“The research sessions were very good and of high quality”

这个学会是以癌症免疫疗法相关研究及技术为主题的一系列活动之一。报名参加这个学会,您除了可以听取这五个学会中将进行的100多场演讲之外,更可拓展您横跨各专门领域的人脉,吸收到崭新的知识。

您可参加同时举办的这系列所有学会

 

2019年10月10日(四) – 治疗癌症所用的抗体


Keynote Address: Development of a next generation immune checkpoint modulator towards the clinic; a humanized BTN3A antibody (ICT01) activating gamm9delta2 T cells
RENE HOET, CSO, Imcheck Therapeutics
ImCheck Therapeutics is advancing the first activating butyrophilin BTN3A (CD277) antibody towards the clinic. The humanized antibody to BTN3A, ICT01, specifically activates human gamma9delta2 T-cells in-vitro and in-vivo and is planned to enter phase I studies early 2020. Additionally, therapeutic antibodies against 5 novel butyrophilins are currently validated. This opens a completely new space clearly different from the current B7/CD28 superfamily targets and has the potential to become the next generation immune checkpoint modulators.

Keynote Address: Cancer Bispecific Biologics: Current Status and Learnings From Successes and Failures
RAKESH DIXIT, VP, Research & Development and Global Head Biologics Safety, MedImmune
• Overview of landscape of bispecifics targeting cancers
• Preclinical and clinical landscape of bispecifics in oncology
• Five rights of bispecifics: A case study of unique immune checkpoints targeting bispecific
• Learnings from success and failures of bispecifics.


Morning Refreshments / Poster Presentations


Triple Negative Breast Cancer targeted therapy with anti-Folate Receptor alpha antibodies
SOPHIA KARAGIANNIS, Reader in Translational Cancer Immunology, Head of Cancer Antibody Discovery and Immunotherapy, King’s College London
Employing a multi-omics approach we show that the folate carrier Folate Receptor alpha (FRα) is upregulated in triple negative breast carcinomas and that expression of molecules involved in the folate metabolism are dysregulated. FRα is expressed in post-neoadjuvant chemotherapy residual disease, and participates in cancer cell signaling and cancer cell growth. We demonstrate that FRα and the folate cascade could be targeted with specific inhibitors. Furthermore, FRα may present a target for antibody immunotherapy that primes an Fc-mediated anti-tumor immune response, and an antibody-drug conjugate approach that can deliver a pathway inhibitor to FRα-expressing cells. These findings may point to a new treatment avenue for patients with triple negative breast cancer.

Targeted Thorium Conjugates: Novel first in class targeted alpha therapy
JENNY KARLSSON, Head of TCR Biochemistry, Bayer
• Targeted thorium conjugates (TTCs) represent a new class of therapeutic radiopharmaceuticals for the targeted alpha therapy (TAT) of cancer.
• TAT has become an established modality in the treatment of metastatic castration-resistant prostate cancer
following the approval of radium-223 dichloride.
• TATs are highly cytotoxic due to the high linear energy transfer of the alpha-particle emitting radionuclide which induces complex DNA double-strand breaks in the targeted tumor cell.
• TTCs consist of a targeting moiety, a chelator covalently linked via an amide bond to the antibody and thorium-227 complexed to the chelator with high affinity.
• Important advantages of TTCs are the lack of known resistance mechanisms to alpha-particle emission and their ability to also kill non-dividing cells.
• Preclinical in vitro and in vivo data will be presented.


Lunch


PANEL DISCUSSION:

Next Generation Antibodies: beyond bispecifics
Speakers include: SYD JOHNSON & RAKESH DIXIT

Bi-specific T-cell Engagers (BiTE®) in Hematological Malignancies
FRANCESCO GALIMI, Global Product General Manager, Early Development, Amgen
The bispecific T-cell engager (BiTE®) blinatumomab (Blincyto®) has recently been approved for Philadelphia
chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It consists of two single chain variable fragments (scFvs) specific for CD19 present on the B-cell lineage, and CD3 expressed on almost all T cells. Based on the potent anti-tumor activity of Blincyto® in B-cell malignancies, BiTE® antibody constructs directed against other target antigens are being tested in a number of malignancies, in particular acute myeloid leukemia and multiple myeloma. We will review the ongoing activities in this field.

Presentation


Afternoon Refreshments / Poster Presentations


POLR2A as a putative predictive biomarker for treatment with Amanitin-based ADCs
CHRISTIAN BREUNIG, Group Leader Biomarker & Cell Biology, Heidelberg Pharma
Heidelberg Pharma develops Antibody Targeted Amanitin Conjugates (ATACs), a new class of Antibody-Drug Conjugates with the cyclic peptide amanitin as the toxic payload. Amanitin blocks the cellular transcription process by specifically binding to the eukaryotic RNA polymerase II. POLR2A, the largest subunit in the human RNA polymerase II complex, is located on chromosome 17p13.1 and in close proximity to TP53. A chromosome 17p deletion is present in any cancer patients correlating with poor survival. Furthermore, we observed that a deletion of POLR2A significantly enhanced treatment efficacy of ATACs in different in vivo models. Based on these observations, Heidelberg Pharma proposes POLR2A as a putative biomarker to identify patients that would benefit the most from treatment with ATACs

Antibody libraries based on an autonomous human variable domain
JOHAN NILVEBRANT, Researcher, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH
Antibodies are tremendously useful for biotechnological applications, diagnostics and therapy. However, their complex architecture has spurred interest in smaller derivatives that can retain the targeting specificity and be more easily produced. We have constructed highly diverse (>1010) libraries based on an autonomous human variable heavy (VH) domain and used these libraries to select specific binders to the human Eph receptor family. Our aim is to use these binders to develop novel tools for specific investigation of blocking or activation of specific Eph receptor homo or heterodimers. Moreover, structural evaluations of first and second-generation binders to EphA1, which have been identified after stress selections on phage, illustrate how VH domains can be stabilized via tailored CDR mutagenesis.


Networking Drinks Reception


2019年10月11日(五) - 癌症免疫疗法的格式

Keynote Address: Developing novel checkpoint inhibitors
JUSTIN SCHEER (Reserved), Director, Antibody Engineering, Boehringer-Ingelheim

BiCKI: a novel Bispecific checkpoint inhibitor platform
NICOLAS POIRIER, CSO, OSE Immunotherapeutics
• A proprietary transformative technology restating the current anti-PD-(L)1 standard of care.
• An engineered anti-PD-1 bispecific platform to extend the spectrum of patients responding to immunotherapies.
• BiCKI is the 2nd generation of PD-x inhibitors to increase the efficacy in hard to treat tumor types by addressing
untapped immune evasion mechanisms.
• OSE’s armed anti-PD-1 bispecifics are paving the way to reinstate sustained adaptive and innate immune responses.


Morning Refreshments / Poster Presentations


Engaging multiple cell populations within immune system with a single mAb: designing Swiss Army knives to fight cancer
ROMAN IVANOV, Vice-President, R&D, BIOCAD
• PDL1/CD47 mAb: restoring Teff response and phagocytosis
• PD1/GITR mAb: shifting the Teff/Treg cell balance
• IL15/PD1 mAb: potentiating Teff and NK responses
• Overcoming stability and manufacturability issues
• Cell-based assays for IO bispecifics
• Selection of in vivo models for IO bispecifics

Advancing t cell engaging antibodies for immuno-oncology
JOHN DESJARLAIS (Reserved), Senior Vice President, Research and Chief Scientific Officer, Xencor


Lunch


Novel antibodies beyond PD-1 therapy for cancer immunotherapy
SONIA QUARATINO, Chief Medical Officer, Kymab

An engineered IgG1-IgM tp fusion for enhanced CDC activity
SHIRLEY PETERS, Principal Scientist, UCB
• IgG1-IgM tp fusion promote IgG1 hexamerisation
• Engineering tp fusion leads to on-target hexamerisation.
• On-target hexamerisation results in enhanced C1q recruitment which translates to enhanced CDC activity

Novel multi-drug immuno-oncology and targeted thearpy combinations lead to synergy in preclinical models of B-cell malignancies
EMMANUEL NORMANT, VP Preclinical Sciences, TG Therapeutics New York
• Drug combinations are critical for efficacy in oncology. TG Therapeutics is building a “combinable” pipeline in order to increase the depth of response, decrease the instances of resistance, and tackle financial toxicity.
• The presentation focuses on datasets from in vitro and in vivo preclinical models that demonstrates synergy. The drugs used are the anti-CD20 antibody ublituximab, the PI3K inhibitor umbralisib, and the novel CD47-CD19 bispecific antibody TG-1801.
• We show here that targeting the innate CD47 checkpoint increases the efficacy of antibody-dependent cellular toxicity (ADCC) and phagocytosis (ADCP) driven by the anti-CD20 antibody ublituximab.
• The anti-tumor activity of the ublituximab and umbralisib “U2” combination is also enhanced with the anti-CD47 bispecific antibody, TG-1801, warranting clinical trial evaluating this triple-therapy.

Engineering a novel check point blockade
STEFAN GLUCK (Reserved), VP GMA, Celgene


Chair’s Closing Remarks / Conference Close


* 活动内容有可能不事先告知作更动及调整。

 

议程

由于这个学会针对的是参与研究配合癌症治疗的抗体医药最新领域人士,所以将吸引350以上该领域的专家。探讨双特异性抗体技术的最新发展,以及探索新抗体和抗体模拟形式的潜力。此外也有以查核点抑制剂为焦点的单元,介绍针对治疗用的PD1,PD-L1和CTLA4的进展,以及新生物标记物的发现和标靶化的研究。

Download the Agenda (PDF)

演讲者

赞助商

所有赞助商名单

地点

London Heathrow Marriott Hotel

London Heathrow Marriott900

Bath Road, Harlington, Hayes, Middlesex, UB3 5AN

海报发表

学会的赞助商

募集赞助商

成为这个学会的赞助商或参展商,您可在融洽的气氛中,一面和专家们交流彼此的意见,同时也有机会和各种组织代表进行官方或非官方会谈,以建立彼此的合作关系。

此外我们更准备了各种赞助商配套方案,您可考量自身的预算及业务需求,选择能让您获得最大投资收益的方案。

如果您有除此之外,成为赞助商来开展您宣传活动的其他建议,也欢迎您随时与我们连络,我们将配合您的需求提供各种提案。

可事前预约的二十分钟一对一个别会谈

在主要会议议程的分组会议期间将举行一系列事先预约的二十分钟个别会谈,选择您想要会见的代表。在会议期间Global Engage的团队将随时待命,确保您的所有会议按时举行。

主要会议前后的研讨会

在主要会议前后,将举办为了对特定主题有兴趣的与会者所办的全天或半天研讨会。Global Engage将协助您在研讨会上进行宣传活动,并确保够多人出席。

学会开幕前的行销和品牌宣传

您也可利用Global Engage的资料库来进行行销,更可揭示海报,成为休息和午餐会、招待会、海报单元的赞助商来提升您的品牌知名度。此外我们也另外提供可在发给与会者的挂绳,和学会资料袋上印刷标志以提升品牌知名度的选项。

参展

会期中,您可在会场内所设的专用区向所有的与会者发表您的技术及产品。展会区同时也是休息及午餐会,第一天傍晚举行的招待会的会场。

演讲

演讲的形态

  • 30分钟的演讲
  • 以主持人或小组成员身分参加30分钟专题研讨会
  • 在学会的议程中召开1小时的研讨会
募集赞助商

详细内容请洽询GII联络处。

包括签证等各种海关所需文件,以及展示用品的通关手续皆由展商企业各自负责。

展示相关的安排(企业介绍、公司商标、提供与会者目录中的展商资讯登录、展示空间的装潢、用品订购、展示用品的摆设搬运、展示空间的文件申请、保险等)请直接与主办方连系。

旅游相关疑问(住宿、机票)、当地翻译人员、飞行与意外保险等问题,将有另外的专门业者分别提供服务。

Novel Antibody Therapeutics Congress的赞助商相关详情请洽询联络处。

媒体合作伙伴

  • 247 Updates
  • Bentham Science
  • Biocompare
  • Biotechgate
  • EIN Presswire
  • Global Information
  • Pharma Journalist
  • PharmaVOICE
  • SciDoc Publishers
  • Pharmaceutical Tech
 
免费电子邮件通知服务